Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
03:48pm, Wednesday, 06'th May 2026
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
11:13am, Saturday, 25'th Apr 2026
Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
12:54pm, Wednesday, 15'th Apr 2026
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside.
SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD
05:07am, Tuesday, 07'th Apr 2026
SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 53.2% during the undefined quarter, according to the company in its most recent 13F filing with the Secur
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
04:45am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
03:07am, Saturday, 14'th Mar 2026
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities a
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
06:07pm, Tuesday, 10'th Mar 2026
Microsoft filed on Tuesday a proposed brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of the AI startup as a �
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
12:15pm, Monday, 23'rd Feb 2026
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC
04:04am, Monday, 23'rd Feb 2026
Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchang
Market Today: Blue Owl payout, GDP miss, oil and EV moves
05:36pm, Friday, 20'th Feb 2026
Guru Stock PicksGeorge Soros has made the following transactions:Reduce in SPSB by 5.19%Sold out in MMYTAdd in AAMI by 61.3%New position in COINStock News Blue
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
04:01pm, Friday, 20'th Feb 2026
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions P
What to Expect From These Drug/Biotech Players This Earnings Season?
03:16pm, Monday, 16'th Feb 2026
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
09:30am, Wednesday, 11'th Feb 2026
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in F
